Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to fight stomach cancer when others fail

NCT ID NCT07371871

Disease control Sponsor: Anhui Provincial Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs, TAS-102 and apatinib, as a third-line treatment for advanced gastric cancer. About 30 adults who have already tried two prior treatments will take these pills in cycles. The goal is to see if the combination can shrink tumors and delay cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Trifluridine/Tipiracil (TAS-102) and Apatinib
What this could lead to
If this works, it could offer a new treatment option for people with advanced gastric cancer who have not responded to earlier therapies.
What could go wrong
This is a small, early exploratory study with only 30 participants and no comparison group. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Gastric cancer confirmed by histopathological or cytological diagnosis; * unresectable locally advanced or recurrent/metastatic gastric cancer; * age 18-75 years, regardless of gender; * ECOG score 0-2; * previously received second-line treatment for advanced gastric cancer with disease progression during or after treatment; * at least one measurable lesion present according to RECIST 1.1 criteria; * laboratory tests meeting the following requirements: (1) Blood routine: HGB≥70g/L; WBC≥4.0×10\^9/L; NEUT≥1.5×10\^9/L; PLT≥90×10\^9/L; (2) Blood biochemistry: ALT, AST≤2.5×upper limit of normal (ULN), serum creatinine≤1.5×upper limit of normal; * negative pregnancy test for patients of childbearing potential and voluntary use of effective and reliable contraception during the trial. Exclusion Criteria: * Participation in other anti-tumor drug clinical trials within 4 weeks prior to enrollment; * Any of the following conditions that may interfere with oral medication: inability to swallow, chronic diarrhea, or intestinal obstruction; * Concurrent receipt of any other systemic anti-tumor therapy (excluding local treatment); * Previous treatment with VEGFR inhibitors (excluding ramucirumab; pan-targeted TKIs are excluded); * Known history of allergy to any component of the study drugs; * Subjects with active infectious diseases; * Patients deemed unsuitable for enrollment by the investigator due to potential increased study-related risks or possible interference with interpretation of study results, as assessed by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced gastric cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.